YouTube probes CRISPR heart approval

The simple answer is no — the FDA has not approved a CRISPR treatment for heart disease. What happened is more technical, and more interesting. Verve Therapeutics got permission to study VERVE-102 in the U.S. and then picked up Fast Track designation, which helps development move faster but is not the same thing as a green light to sell a drug. ### What drug are people talking about? The drug is VERVE-102, an in vivo base-editing treatment for people with very high cardiovascular risk, including heterozygous familial hypercholesterolemia and some patients with premature coronary artery disease. It is designed to turn off the PCSK9 gene in the liver after a single infusion, with the goal of lowering LDL cholesterol for a long time — maybe for life. (vervetx.com) ### Why does “in vivo” matter here? Because this is the hard version of gene editing. Casgevy — the first FDA-approved CRISPR therapy — edits a patient’s blood stem cells outside the body and then puts them back. VERVE-102 is different. The editing machinery goes directly into the body and is supposed to make the change inside liver cells. That is a much bigger regulatory and safety challenge, which is why people are watching it so closely. (vervetx.com) ### So what did the FDA actually do? Two things. On March 24, 2025, the FDA cleared Verve’s Investigational New Drug application for VERVE-102. That meant the company could activate U.S. trial sites. Then, on April 11, 2025, the FDA granted Fast Track designation for certain high-risk hyperlipidemia populations. Fast Track can mean more meetings with the agency and rolling review later on, but it is still a development-stage status, not approval. (fda.gov) ### What is Fast Track not? It is not approval, not a label, and not proof that the FDA thinks the drug works. Basically, it says the agency sees a serious condition and a plausible unmet need worth moving along more efficiently. If a drug eventually reaches the finish line, it still has to survive the normal evidence grind — larger trials, cleaner safety data, and a formal marketing application. (vervetx.com) ### What data does Verve have so far? Early Heart-2 data announced on April 14, 2025 looked encouraging but still very early. Verve said 14 participants had been treated across the first three dose cohorts, with no treatment-related serious adverse events and no clinically significant ALT or platelet changes. In the 0.6 mg/kg cohort, LDL fell by a mean 53%, with a maximum reduction of 69%. That is the kind of number that gets attention — but it came from a small Phase 1b study built mainly to test safety. (vervetx.com) ### Why are people still saying VERVE-101? Because VERVE-101 was Verve’s earlier PCSK9 program, and it became the headline magnet when the company first showed proof that base editing could lower LDL in humans. But the newer regulatory milestones in 2025 were for VERVE-102, not VERVE-101. If a video says “the FDA approved VERVE-101,” that is just wrong. ### Has any CRISPR medicine been approved at all? (vervetx.com) Yes — but not for heart disease. The FDA approved Casgevy on December 8, 2023 for sickle cell disease, making it the first FDA-approved therapy that uses CRISPR/Cas9. That milestone is real. It just does not extend to Verve’s cardiovascular programs. ### Why does this still matter? (vervetx.com) Because cardiology is the giant prize. A one-time treatment that permanently lowers LDL could change prevention for people who struggle to stay on lifelong cholesterol drugs. The catch is permanence cuts both ways — if safety problems show up, you cannot just stop taking the medicine like you can with a statin. That is why “promising trial” and “approved therapy” are worlds apart. (fda.gov) The bottom line is that the YouTube question points at a real milestone, but labels it too aggressively. Verve has an investigational CRISPR-style heart program with FDA IND clearance and Fast Track status. It does not have FDA approval. (vervetx.com)